47 Recent breakthroughs in colorectal cancer research have unveiled a profound understanding of the disease’s underlying mechanisms, highlighting pathways critical to its progression. These discoveries are now shaping innovative treatment strategies aimed at improving survival rates. The findings were published in the journal Signal Transduction and Targeted Therapy. Colorectal cancer, ranked as the third most prevalent cancer worldwide, claims nearly a million lives annually. Its development is largely influenced by genetic and epigenetic changes that disrupt key signalling pathways. Among these, the Wnt/β-catenin pathway, often altered by mutations in the APC gene, plays a pivotal role in driving tumour growth and immune system evasion. Parallel disruptions in the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK cascades amplify the malignant transformation of cells. The rise of precision medicine has shifted the landscape of colorectal cancer treatment. Unlike traditional chemotherapy, which broadly targets dividing cells, precision therapies exploit specific molecular alterations within tumours. Drugs targeting the epidermal growth factor receptor (EGFR) have shown promise in combating advanced disease, though resistance remains a challenge. Similarly, inhibitors addressing mutations in the PI3K or RAS pathways are being refined to overcome therapeutic limitations. Another area of advancement is the integration of artificial intelligence to enhance patient stratification. By analysing complex genomic and epigenomic data, AI tools are identifying patterns that help personalise treatment plans. This approach is particularly relevant for therapies targeting epigenetic changes, such as abnormal DNA methylation or histone modifications, which frequently occur in colorectal cancer. Recent studies have also shed light on the role of the tumour microenvironment in cancer progression. Interactions between cancer cells and their surrounding tissues significantly influence treatment outcomes. Immunotherapies, designed to harness the body’s immune system, are proving effective in cases characterised by high microsatellite instability. Meanwhile, combinations of targeted drugs and immunotherapies are being explored to tackle resistant cancers. Screening and early detection remain vital in reducing colorectal cancer mortality. Advances in understanding the disease’s progression – from benign polyps to invasive carcinomas—underscore the importance of timely intervention. Technologies enabling non-invasive biomarker detection are enhancing the accuracy of early diagnosis. Colorectal cancer research continues to face hurdles, including the complex interplay of signalling pathways and resistance mechanisms. However, ongoing efforts to unravel these complexities promise more effective, personalised treatments.